← Back to Search

Monoclonal Antibodies

Rituxan for Inflammation and Pain

N/A
Waitlist Available
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks, 24 weeks
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

The purpose of this investigation is to determine the effects of Rituxan therapy in individuals with rheumatoid arthritis on endothelial function and other markers of endothelial function

Eligible Conditions
  • Inflammation and Pain
  • Inflammation
  • Flow-mediated Dilatation
  • Rheumatoid Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks, 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks, 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Flow-mediated Vasodilation (FMD)

Side effects data

From 2013 Phase 4 trial • 40 Patients • NCT00782821
50%
CTCAE Grade 1 Diarrhea
30%
CTCAE Grade 1 Nausea/Vomiting
30%
CTCAE Grade 2 Nausea/Vomiting
30%
CTCAE Grade 2 Diarrhea
20%
CMV Invasive Disease
20%
BKV Viremia
20%
CMV Viremia
10%
CMV +/- Status
10%
CTCAE Grade 3 Diarrhea
10%
CTCAE Grade 3 Nausea/Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
RATG/Rituxan/Velcade
RATG/Rituxan
Rabbit Antithymocyte Globulin (RATG)
RATG/Velcade

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RituxanExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,589 Previous Clinical Trials
14,901,339 Total Patients Enrolled
Genentech, Inc.Industry Sponsor
1,564 Previous Clinical Trials
570,626 Total Patients Enrolled
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top